Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2023-11-29 AGM Information
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Result of AGM
AGM Information Classification · 99% confidence The document is a short announcement (3595 characters) released via RNS (Regulatory News Service) with the title "Result of Annual General Meeting". It explicitly states that "all resolutions proposed at the Annual General Meeting held today were duly passed." This content directly relates to the outcome of the AGM. According to the definitions, 'AGM Information (Code: AGM-R)' covers presentations and materials shared during the AGM. Since this is the official result announcement following the meeting, AGM-R is the most appropriate classification, rather than a general Regulatory Filing (RNS) or a Proxy Solicitation (PSI) which precedes the meeting.
2023-11-29 English
Update on SCOPE trial
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' header and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). It provides an update on a clinical trial ('SCOPE trial') for Scancell Holdings Plc, including response rates and next steps. The closing section explicitly states: "This information is provided by RNS, the news service of the London Stock Exchange." This strongly indicates a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), a dividend notice (DIV), or a formal proxy statement (DEF 14A), the most appropriate general category for LSE regulatory news that doesn't fit elsewhere is 'Regulatory Filings' (RNS). The document length is moderate, but its primary function is disseminating time-sensitive operational/clinical news via the RNS system.
2023-11-28 English
Scancell to present at 20th SMR Congress
Regulatory Filings Classification · 98% confidence The document begins with an RNS Number and a date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content announces that data from a Phase 2 clinical trial (SCOPE trial) was presented at a medical congress. It details the presentation title, author, session time, and provides contact information for brokers and PR. Crucially, it states that the abstract will be made available on the company's website. This structure—announcing the presentation of data and directing the reader elsewhere for the full details/abstract—is characteristic of a general regulatory update rather than a full financial report (10-K, IR) or a specific management/governance filing. Since it is a general regulatory announcement disseminated via RNS and doesn't fit the specific categories like ER, CT, or DIRS, the most appropriate classification is the general regulatory filing category, RNS.
2023-11-10 English
Group of companies' accounts made up to 2023-04-30
Regulatory Filings
2023-11-06 English
Scancell to present at 38th Annual SITC meeting
Report Publication Announcement Classification · 99% confidence The document is identified by the RNS Number (9469R) and the header 'National Storage Mechanism', indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content announces that data from a clinical trial (Phase 2 SCOPE trial) has been selected for a poster presentation at an external conference (SITC). This is not the full report (like 10-K or IR), nor is it a general earnings release (ER) or a formal proxy statement. Since it is a specific, time-sensitive announcement of company news distributed through the official regulatory channel (RNS), and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory announcement category, RNS, as it is a standard regulatory news service release.
2023-11-01 English
Notice of AGM
AGM Information Classification · 98% confidence The document is an RNS announcement (RNS Number : 8847R) dated October 31, 2023. The title explicitly states 'Annual Report and Notice of Annual General Meeting'. It informs shareholders that the 'Annual Report and Accounts for the year ended 30 April 2023' and the 'Notice of Annual General Meeting ("AGM") will be sent to shareholders shortly.' It also provides the date and location for the AGM. Because the document is short (4491 chars) and its primary function is to announce the publication/mailing of the Annual Report and the AGM details, it fits the definition of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) or the AGM materials (AGM-R) themselves. However, since it specifically mentions both the Annual Report and the AGM Notice, and given the presence of the AGM details, classifying it as an announcement related to the AGM (AGM-R) or the Report Publication (RPA) is necessary. Since the core purpose is announcing the availability of the Annual Report and the AGM details, and it is a regulatory filing format (RNS), RPA is the most accurate fit based on the 'MENU VS MEAL' rule, as it is an announcement *about* the reports/meeting, not the reports/meeting content itself. If RPA wasn't available, RNS would be the fallback. Given the strong mention of the AGM, AGM-R is also plausible, but RPA captures the announcement nature better.
2023-10-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.